These approaches are important for understanding the regulation of specific noncanonical pathways in which drugs do not modulate RORα via LBDs, suggesting that a mechanism-based drug administration strategy may be useful for specifically inhibiting cancer activity. This evidence concerns the gene RORA and cancer.